Anti-DR5 [YSd1]

Absolute Antibody

Anti-DR5 [YSd1]

7

YSd1 bound DR5 with high affinity, shown using competitive phage ELISA as well as surface plasmon resonance (with a Kd of 34 nM). By binding to interfacial regions of DR5 which are sites of physiological ligand interaction, it is likely that YSd1 has the capacity to neutralise DR5 activity by inhibition of downstream signalling.

Neutralisation/Blocking

NTRL

Research Use Only

Monoclonal

YSd1

TNFRSF10B

TNF receptor superfamily member 10b

CD262, DR5, KILLER, KILLER/DR5, TRAIL-R2, TRAILR2, TRICK2, TRICK2A, TRICK2B, TRICKB, ZTNFR9, tumor necrosis factor receptor superfamily member 10B, Fas-like protein, TNF-related apoptosis-inducing ligand receptor 2, apoptosis inducing protein TRICK2A/2B, apoptosis inducing receptor TRAIL-R2, cytotoxic TRAIL receptor-2, death domain containing receptor for TRAIL/Apo-2L, death receptor 5, p53-regulated DNA damage-inducible cell death receptor(killer), tumor necrosis factor receptor superfamily, member 10b, tumor necrosis factor receptor-like protein ZTNFR9

Human

IgG1

Tumor necrosis factor receptor superfamily member 10B

This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques.

-20°C,2°C to 8°C

41116161